hIL3-hCSF2-Tg(M-NSG)
品系全名
NOD.Cg-PrkdcscidIl2rgem1Tg(hIL3-hCSF2)Smoc
目录号
NM-KI-215006
品系状态
活体
基因信息
基因名
IL3
基因名
CSF2
品系描述
验证数据
Fig.1 Detection of hCSF2(A) and hIL3(B) expression in serum by ELISA (n=3).
Abbr. HO, homozygous; N.D. not detected.
Fig. 2 Human immune cell phenotyping in hIL3-hCSF2-transgenic (M-NSG) engrafted with human HSCs. Human CD34+ cells (1.0×10^5) were intravenously injected into homozygous hIL3-hCSF2-transgenic (M-NSG) pretreated with 1.0 Gy irradiation. These results demonstrate successful engraftment and propagation of human T, B, Myeloid and Momocytescells in the hIL3-hCSF2-transgenic (M-NSG) model.
发表文献 1篇
你也可能感兴趣
Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
查看Workshop：Progress and Advances in Preclinical immuno-Oncology Research
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
查看Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
查看
